MIRA
INFORM REPORT
|
Report Date : |
21.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
LABORATORIO RAFFO
S.A. |
|
|
|
|
Registered Office : |
Agustin Alvarez 4145, Villa Martelli, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1958 |
|
|
|
|
Legal Form : |
Public Limited Company |
|
|
|
|
Line of Business : |
Engaged in the elaboration and commercializaztion of medicinal specialities for human use. |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Registered Name
LABORATORIO RAFFO S.A.
CUIT
30-50209419-6
Summary
INCORPORATED IN 1958. BEGINNER OF ACTIVITIES. FINANCIAL
INFORMATION IS NOT SUPPLIED. IT HAS A
Operations
MEDICINAL SPECIALITIES
ELABORATION
COMMERCIALIZATION
Legal Structure
Business type: Public Limited Company
Incorporated: 1958
Registered: 19/03/1958
Register #: 8.409
Duration: 99 years
End of fiscal year: December 31st
Contact
Carlos Garro (Employee)
Legal and Operative address: Agustin Alvarez 4145, Villa Martelli,
Phone: (54-11) 6347-7100
E-mail: harantino@raffo.com.ar
Website: www.laboratoriosraffo.com.ar
Partners
President: JULIO RODRIGUEZ
Vice-president: PATRICIO MARTIN RODRIGUEZ
Director: GASTON RODRIGUEZ
Social signature use: In the charge of the President and Vice-president.
Corporate Stock
It is known that its parent company is MONTE VERDE S.A., from which no details were obtained.
History
The company is beginner of activities and was incorporated in 1958. As time goes by, it changed its name several times. It started operating as "Laboratorios Profesor Raffo S.A.I.C.Y.F.", later on it operated as "Laboratorios Dr. Raffo S.A.I.C.F." for finally change its name to the current one.
Economic-Financial
Position
Categorical refusal from the company's representatives to supply financial information.
It is known that the company's activities are related to the elaboration and
commercialization of medicinal specialities.
It has been mentioned that 90% of it medicaments nowadays depends on MONTE
VERDE S.A., with headquarters in
Parent/Related
Companies
MONTE VERDE S.A.
---------------
Production plant:
Monthly production: 30 millions of pills and medicinal specialities.
Its products are sold in the country and abroad.
Laboratorio Raffo managed to be the first growing lab in the country during
three consecutive years, since it has 750 employees and broke records of
turnover in the last three years.
Publications as of December/2006 said that the company of pharmaceutical
products Monte Verde SA will invest more than US$ 20 millions for enlarging its
production plant. With this investment, the company would be able to treble its
exports and quadruple the production, which will be of 100 millions of pills.
The plant of Monte Verde SA is located in Ruta 40 entre 7 y 8 of Pocito,
Evolution and
Results
The company is engaged in the elaboration and commercializaztion of medicinal specialities for human use.
These activities are led by the main directors, who work together with 10
people.
The company's current draft is very limited since most of its operations are
carried out through its parent company MONTE VERDE S.A.
FOREIGN TRADE:
--------------
In the last twelve months it has carried out imports for a total value of US$
2.725.949 from the following countries:
OTHER COUNTRIES 86.551
-----------------------
Human blood
Prepared animal blood for therapeutic preventive use or of antiserum diagnosis
Serum with antibodies
Modified immunological products
Several vaccines
Vaccines against flu
Several medicaments
Payment Record and
Credit Risk
BANKS:
------
BBVA BANCO
BANCO CREDICOOP
It doesn't register issuances of non-sufficient-funds checks.
Concept
It doesn't register negative records.
According to our investigations, the company complied in due time the
commitments taken and has a good concept.
* FULFILLMENT: WITHOUT OBJECTIONS
Final Opinion
What has been exposed hereby is all as regards this company. For its credit treatment we suggest operating by moderated amounts with the adoption of additional guarantees.
* FIT FOR MODERATED CREDITS WITH THE ADOPTION OF GUARANTEES
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)